SuperworthActuate Therapeutics price to book ratio ACTU
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 11.5×
- Peer median
- 1.6×
Actuate Therapeutics' price to book ratio is 11.5× as of Oct 23, 2026.
The median for 3 large drugmakers of a similar size is 1.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 11.5× | 5.0× | 40.3× |
| 2025 | 13.8× | 12.6× | 36.8× |
| 2024 | 32.2× | 24.7× | 32.7× |
Against its peers
Companies in Drug Manufacturers - General nearest Actuate Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| ACTUActuate Therapeutics | 11.5× |
| ATNMActinium Pharmaceuticals | 1.6× |
| SPROSpero Therapeutics | 1.5× |
| LFVNLifevantage | 2.2× |
| Peer median | 1.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Actuate Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.